Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentavalent reassortant rotavirus attenuated live vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The pentavalent reassortant rotavirus attenuated live vaccine (referred to in Sinovac's pipeline and clinical trials as a hexavalent vaccine) is an oral, live-attenuated biologic developed by Sinovac Life Sciences for the prevention of rotavirus gastroenteritis in infants and young children. The vaccine is designed to provide broad-spectrum protection against the most prevalent rotavirus strains, specifically targeting six serotypes: G1, G2, G3, G4, G9, and P[8] (P1A). This coverage is broader than existing pentavalent vaccines like RotaTeq, as it includes the G9 serotype which has become increasingly common in China and globally. The vaccine is produced using Vero cell technology and is administered orally in a three-dose regimen. It is currently in Phase II clinical development, following the initiation of Phase I trials in early 2024.
- Other names
- Oral hexavalent reassortant rotavirus attenuated live vaccineHexavalent Rotavirus Vaccine (Vero Cell)Sinovac rotavirus vaccine
02
Targets
RVA (Rotavirus A)
Beyond the preview
Go deeper on pentavalent reassortant rotavirus attenuated live vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentavalent reassortant rotavirus attenuated live vaccine.